Placebo cohorts in phase-3 MS treatment trials - predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case data.
BACKGROUND: Annualized relapse rates (ARR) in the placebo cohorts of phase-3 randomized controlled trials (RCT) of new treatments for relapsing remitting multiple sclerosis (RRMS) have decreased substantially during the last two decades. The causes of these changes are not clear. We consider a bette...
Main Authors: | Jan-Patrick Stellmann, Anneke Neuhaus, Lena Herich, Sven Schippling, Matthias Roeckel, Martin Daumer, Roland Martin, Christoph Heesen |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3510222?pdf=render |
Similar Items
-
Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review.
by: Jan-Patrick Stellmann, et al.
Published: (2014-01-01) -
Regression to the mean and predictors of MRI disease activity in RRMS placebo cohorts--is there a place for baseline-to-treatment studies in MS?
by: Jan-Patrick Stellmann, et al.
Published: (2015-01-01) -
Short-term MRI measurements as predictors of EDSS progression in relapsing-remitting multiple sclerosis: grey matter atrophy but not lesions are predictive in a real-life setting
by: Johanna von Gumberz, et al.
Published: (2016-09-01) -
Prognostic risk estimates of patients with multiple sclerosis and their physicians: comparison to an online analytical risk counseling tool.
by: Christoph Heesen, et al.
Published: (2013-01-01) -
Feasibility of a smartphone app to enhance physical activity in progressive MS: a pilot randomized controlled pilot trial over three months
by: Navina N. Nasseri, et al.
Published: (2020-06-01)